Tokyo, Oct. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058501) titled 'Prevalence, diagnosis, and treatment of migraine due to iron deficiency' on Oct. 1.

Study Type: Observational

Primary Sponsor: Institute - International University of Health and Welfare

Condition: Condition - Migraine Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - Iron deficiency has been attracting attention as a possible modifying factor involved in the pathology of migraine, and its comorbidity has been reported, especially in young women. Neuroimaging studies have suggested abnormalities in intracerebral iron deposition in migraine patients, and abnormal iron metabolism may affect migraine susceptibility and treatment response. However, accurate clinical assessment of iron deficiency is difficult because the diagnostic criteria for iron deficiency are not unified and the prevalence varies greatly depending on the evaluation method. In recent years, the introduction of CGRP-targeted drugs has made great progress in preventive treatment of migraine, but there are still cases in which sufficient efficacy is not achieved. Iron deficiency is common and can be improved by appropriate intervention, so it is clinically important as a potential intervention target that can improve treatment response. In this study, we will clarify the prevalence of iron deficiency in migraine patients based on standard diagnostic criteria and examine whether iron supplementation therapy can complement the preventive treatment effect. We will also evaluate the usefulness of iron supplementation monotherapy in pregnant and lactating patients and consider the importance of iron supplementation therapy in migraine treatment. Basic objectives2 - Efficacy

Eligibility: Age-lower limit - 6 years-old = Gender - Male and Female Key inclusion criteria - Patients who visited a participating facility for outpatient treatment with migraine between April 1, 2022 and May 22, 2025. Key exclusion criteria - Patients with vertebral artery dissection, brain tumor, or other vascular disorders were excluded. Patients with insufficient data on iron-related parameters were excluded. Target Size - 631

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 08 Month 15 Day Anticipated trial start date - 2025 Year 10 Month 01 Day Last follow-up date - 2026 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066885

Disclaimer: Curated by HT Syndication.